Brief summary

Title: Vesicular Drug Delivery System for Skin Cancer

Summary

One of the most prevalent malignancies with a large number of reported morbidities is skin cancer, which calls for a cutting-edge therapy with improved chemotherapeutic outcomes. Conventional treatment falls short of the anticipated therapeutic effectiveness due to a high level of drug resistance. Transethosomes (TEs), a new era of nanovesicles that enable effective contact with cancer cells, have been employed to alleviate the bottleneck. Studies in silico were carried out to comprehend interacted fluorouracil (FU) and Carvedilol (CVD) with key melanoma receptors. A robust HPLC method was developed for evaluation of drugs. We created the Fluorouracil (FU) and Carvedilol (CVD) loaded transethosomal carrier hybrid gel (FU-CVD-TEs gel) for a combination treatment. By using the ethanol injection approach and then probing sonication, transethosomes were created. Using Box Benken design, the TEs were optimized, with an average particle size and zeta potential of 113.7 nm, 27.3 mV respectively. Utilizing cutting-edge methods like FTIR, DCS, SEM, TEM, AFM, Raman Spectra, and XRD along with encapsulation efficiency (%EE) and stability, the optimized formulation was assessed in accordance with ICH guidelines. Preclinical research involved blood haemolysis and in-vitro cell lines. Comparative research with various vesicular systems, including transferosomes, liposomes, and ethosomes, was assessed. Furthermore, transethosomal nanocarriers effectively delivered both medications in the epidermal layers, as shown by in vitro and ex vivo drug penetration experiments. Additionally, when compared to the Individual formulation, the generated FU-CVD-TEs shown good results in in vitro HACAT cell investigations, including MTT assays, Cell Cycle Analysis, Cellular Apoptosis, Reactive Oxygen Species (ROS) Analysis, and wound healing. Additionally, dermatokinetic experiments indicate that using FU-CVD-TEs improved drug deposition at both the epidermal and dermal layers. In addition, skin cancer cells treated to FU-CVD-TEs displayed the DNA fragmentation assay-proven apoptosis. Propidium iodide (PI) was used to analyze the cell cycle, and with annexin FITC, DAPI, and Merged reagents to identify apoptosis. Optimized TEs Gel were evaluated In-vitro, Ex-vivo on albino rat skin and human cadaver skin that drugs permeation both drugs maximum retention in the skin layers. Studies on Wister albino rats showed that FU-CVD-TEs in hybrid Gel was significantly more tolerable and less irritating than traditional therapy. displays the skin retention behaviour of the formulation in addition. Later, in-vivo UV Irradiation research showed on Wister albino rat that formulated CVD-FU-

TEs hybrid gel were substantially more effective in reduced tumor than traditional formulation. As a consequence, the obtained results showed that FU-CVD-TEs gel may be a more effective carrier of FU and CVD than traditional gel for penetration and disposition into various layers of the skin. Additionally, the produced formulation demonstrated enhanced larger tumor diminution, better endurance rate, and decreased tumor number, area, and volume. As a result, produced transethosomes based hybrid gel could be a useful formulation strategy for the treatment of skin cancer. Final results of the study presented a novel combinatorial chemotherapy that may be used to treat skin cancer.

Nominator



Dr. Sankha Bhattacharya
Asso. Professor and Head
Department of Pharmaceutics,
School of Pharmacy and Technology management,
SVKM'S NMIMS, Mumbai